Related Experiment Videos

Cytokine targeting in psoriasis and psoriatic arthritis: beyond TNFalpha

I B MclInnes1

  • 1Division of Immunology, Infection and Inflammation, University of Glasgow, Centre for Rheumatic Diseases, Glasgow, Scotland. i.b.mcinnes@climed.gla.ac.uk

Ernst Schering Research Foundation Workshop
|December 7, 2005
PubMed

Insights

Interleukin-15 (IL-15) is a key driver of psoriasis inflammation. Blocking IL-15 shows promise in treating psoriatic skin conditions and related inflammatory diseases.

Area of Science:

  • Immunology
  • Dermatology
  • Cytokine Biology

Background:

  • Pro-inflammatory cytokines, like TNFalpha, are validated targets in cutaneous inflammation such as psoriasis.
  • Psoriatic skin and synovium exhibit significant cytokine and chemokine activity, presenting novel therapeutic opportunities.

Purpose of the Study:

  • To investigate the role of Interleukin-15 (IL-15) as a therapeutic target in psoriasis.
  • To evaluate the efficacy of IL-15 blockade in a murine model of psoriasis.

Main Methods:

  • Analysis of cytokine and chemokine profiles in psoriatic skin and synovium.
  • Assessment of IL-15's role in leukocyte activation, T cell memory, and apoptosis prevention.
  • Administration of IL-15 blockade in a murine model of psoriasis.

Main Results:

  • IL-15 is upregulated in psoriatic skin and psoriatic arthritis synovium.
  • IL-15 blockade in a murine psoriasis model significantly suppressed characteristic skin lesions.
  • Early clinical trials targeting IL-15 in other inflammatory diseases show encouraging efficacy.

Conclusions:

  • IL-15 is a critical pro-inflammatory cytokine implicated in the pathogenesis of psoriasis.
  • Targeting IL-15 presents a promising novel therapeutic strategy for psoriasis and potentially other chronic inflammatory diseases.

Related Concept Videos

T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...